PDS Biotechnology (PDSB) News Today → Write this ticker symbol down… (From StocksToTrade) (Ad) Free PDSB Stock Alerts $3.11 +0.03 (+0.97%) (As of 05/28/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 20, 2024 | americanbankingnews.comPDS Biotechnology Co. Forecasted to Post FY2024 Earnings of ($1.29) Per Share (NASDAQ:PDSB)May 17, 2024 | marketbeat.comQ2 2024 Earnings Estimate for PDS Biotechnology Co. (NASDAQ:PDSB) Issued By HC WainwrightPDS Biotechnology Co. (NASDAQ:PDSB - Free Report) - Equities researchers at HC Wainwright lifted their Q2 2024 EPS estimates for PDS Biotechnology in a research report issued to clients and investors on Wednesday, May 15th. HC Wainwright analyst J. Pantginis now expects that the company will earnMay 16, 2024 | marketbeat.comFY2028 Earnings Estimate for PDS Biotechnology Co. (NASDAQ:PDSB) Issued By HC WainwrightPDS Biotechnology Co. (NASDAQ:PDSB - Free Report) - Stock analysts at HC Wainwright increased their FY2028 earnings per share (EPS) estimates for shares of PDS Biotechnology in a research report issued on Wednesday, May 15th. HC Wainwright analyst J. Pantginis now expects that the company will eaMay 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for PDS Biotechnology on Strong Financials and Promising Clinical PipelineMay 15, 2024 | investorplace.comPDSB Stock Earnings: PDS Biotechnology Beats EPS for Q1 2024May 15, 2024 | marketbeat.comPDS Biotechnology (NASDAQ:PDSB) Given "Buy" Rating at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $21.00 price objective on shares of PDS Biotechnology in a research note on Wednesday.May 15, 2024 | sfgate.comPDS Biotechnology: Q1 Earnings SnapshotMay 15, 2024 | msn.comPDS Biotechnology GAAP EPS of -$0.30 beats by $0.06May 15, 2024 | globenewswire.comPDS Biotech Provides Business Update and Reports First Quarter 2024 Financial ResultsMay 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for PDS Biotechnology on Promising Clinical Data and Strategic FocusMay 9, 2024 | markets.businessinsider.comBuy Rating Affirmed on PDS Biotechnology’s Promising HNSCC Treatment DevelopmentsMay 9, 2024 | globenewswire.comPDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck CancerMay 9, 2024 | finance.yahoo.comPDS Biotech to Participate in Upcoming May 2024 Investor ConferencesMay 8, 2024 | marketbeat.comPDS Biotechnology (PDSB) to Release Earnings on WednesdayPDS Biotechnology (NASDAQ:PDSB) will be releasing earnings before the market opens on Wednesday, May 15, Zacks reports.May 7, 2024 | finance.yahoo.comPDS Biotech to Announce First Quarter 2024 Financial Results on May 15, 2024May 3, 2024 | globenewswire.comPDS Biotechnology Announces Details of Virtual KOL EventMay 2, 2024 | globenewswire.comPDS Biotech Appoints Stephan Toutain as Chief Operating OfficerApril 29, 2024 | seekingalpha.comPDS Biotechnology: Entering A Holding Pattern While Cash Remains A Concern (Rating Downgrade)April 23, 2024 | globenewswire.comPDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck CancerApril 20, 2024 | finance.yahoo.comPDS Biotechnology Corporation (PDSB)April 20, 2024 | marketbeat.comPDS Biotechnology (NASDAQ:PDSB) Trading Down 8.8%PDS Biotechnology (NASDAQ:PDSB) Stock Price Down 8.8%April 5, 2024 | investing.comPDS Biotechnology Corp (PDSB)April 3, 2024 | msn.comLuminous quasar PDS 456 explored with MUSEMarch 30, 2024 | finance.yahoo.comPDS Biotechnology Corporation's (NASDAQ:PDSB) market cap dropped US$1.5m last week; individual investors who hold 59% were hit as were institutionsMarch 29, 2024 | ca.style.yahoo.comTwitch online gamer Ninja says he has form of skin cancer in 'early stages'March 29, 2024 | marketbeat.comPDS Biotechnology Co. (NASDAQ:PDSB) to Post Q1 2024 Earnings of ($0.40) Per Share, B. Riley ForecastsPDS Biotechnology Co. (NASDAQ:PDSB - Free Report) - Equities researchers at B. Riley issued their Q1 2024 EPS estimates for PDS Biotechnology in a research note issued on Thursday, March 28th. B. Riley analyst M. Mamtani forecasts that the company will post earnings of ($0.40) per share for the qMarch 28, 2024 | finance.yahoo.comPDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2023 Earnings Call TranscriptMarch 28, 2024 | marketbeat.comPDS Biotechnology (NASDAQ:PDSB) Stock Rating Reaffirmed by B. RileyB. Riley reaffirmed a "buy" rating and issued a $11.00 target price (down from $14.00) on shares of PDS Biotechnology in a report on Thursday.March 28, 2024 | marketbeat.comResearch Analysts Offer Predictions for PDS Biotechnology Co.'s FY2028 Earnings (NASDAQ:PDSB)PDS Biotechnology Co. (NASDAQ:PDSB - Free Report) - Investment analysts at HC Wainwright issued their FY2028 earnings estimates for PDS Biotechnology in a report issued on Wednesday, March 27th. HC Wainwright analyst J. Pantginis expects that the company will post earnings of $0.33 per share forMarch 28, 2024 | finance.yahoo.comQ4 2023 PDS Biotechnology Corp Earnings CallMarch 27, 2024 | finance.yahoo.comPDS Biotechnology Corp (PDSB) Reports Full Year 2023 Financial Results and Clinical Strategy UpdateMarch 27, 2024 | investorplace.comPDSB Stock Earnings: PDS Biotechnology Beats EPS for Q4 2023March 27, 2024 | marketbeat.comHC Wainwright Reiterates "Buy" Rating for PDS Biotechnology (NASDAQ:PDSB)HC Wainwright reaffirmed a "buy" rating and set a $21.00 price objective on shares of PDS Biotechnology in a research note on Wednesday.March 27, 2024 | globenewswire.comPDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial ResultsMarch 27, 2024 | msn.comPDS Biotechnology FY 2023 Earnings PreviewMarch 21, 2024 | marketbeat.comPDS Biotechnology (PDSB) Scheduled to Post Quarterly Earnings on WednesdayPDS Biotechnology (NASDAQ:PDSB) will be releasing earnings before the market opens on Wednesday, March 27, Zacks reports.March 20, 2024 | globenewswire.comPDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial ResultsMarch 18, 2024 | msn.comMP: Authorities Grappling With Suspicious PDS Wheat Black MarketingMarch 17, 2024 | msn.comMP: Police Seize 30 Sacks Of PDS Rice Out For Black MarketingMarch 14, 2024 | msn.comGFA, PDS Ventures to invest $200,000 in new fashion innovatorsMarch 13, 2024 | investorplace.comThe 3 Most Undervalued Biotech Stocks to Buy in March 2024March 13, 2024 | globenewswire.comPDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune®March 8, 2024 | marketbeat.comPDS Biotechnology (NASDAQ:PDSB) Raised to "Hold" at StockNews.comStockNews.com raised shares of PDS Biotechnology from a "sell" rating to a "hold" rating in a report on Friday.January 26, 2024 | seekingalpha.comPDS Biotechnology: Advancement Of PDS0101 Continues With Expansion DataJanuary 23, 2024 | msn.comPDS Biotech names Kirk V. Shepard as Chief Medical OfficerJanuary 16, 2024 | finance.yahoo.comPDS Biotech to Participate at B. Riley Securities 4th Annual Oncology ConferenceJanuary 16, 2024 | finance.yahoo.comPDS Biotech to Participate at B. Riley Securities 4th Annual Oncology ConferenceJanuary 2, 2024 | finance.yahoo.comAll You Need to Know About PDS Biotechnology (PDSB) Rating Upgrade to BuyDecember 21, 2023 | marketbeat.comResearch Analysts Set Expectations for PDS Biotechnology Co.'s FY2023 Earnings (NASDAQ:PDSB)PDS Biotechnology Co. (NASDAQ:PDSB - Free Report) - Analysts at Cantor Fitzgerald issued their FY2023 EPS estimates for shares of PDS Biotechnology in a research report issued to clients and investors on Monday, December 18th. Cantor Fitzgerald analyst L. Chen forecasts that the company will postDecember 21, 2023 | marketbeat.comPDS Biotechnology (NASDAQ:PDSB) Given "Overweight" Rating at Cantor FitzgeraldCantor Fitzgerald reaffirmed an "overweight" rating on shares of PDS Biotechnology in a research note on Monday. Get PDS Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for PDSB and its competitors with MarketBeat's FREE daily newsletter. Email Address Tech GIANT’s Plans to Revolutionize Crypto… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. PDSB Media Mentions By Week PDSB Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PDSB News Sentiment▼1.440.85▲Average Medical News Sentiment PDSB News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PDSB Articles This Week▼32▲PDSB Articles Average Week Get PDS Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for PDSB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: OPTN News Today RNAC News Today RGLS News Today KPTI News Today CTXR News Today ACET News Today ALLK News Today GNLX News Today AMLX News Today CRVS News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PDSB) was last updated on 5/29/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaA once-in-a-century investment opportunityStansberry ResearchWrite this ticker symbol down…StocksToTradeYou won't believe what Citigroup just did to it's depositorsAmerican AlternativeWARNING about the death of the U.S. dollar…Colonial MetalsMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PDS Biotechnology Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
